Monoclonal antibodies (mAbs) targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) or the programmed cell death protein 1 pathway (PD-1/PD-L1) are already being applied clinically to treat a variety of human cancers, especially advanced solid tumors [5, 6]. This evidence concerns the gene CD274 and cancer.